2,438 reports of this reaction
2.2% of all METFORMIN HYDROCHLORIDE reports
#8 most reported adverse reaction
DYSPNOEA is the #8 most commonly reported adverse reaction for METFORMIN HYDROCHLORIDE, manufactured by Santarus, Inc.. There are 2,438 FDA adverse event reports linking METFORMIN HYDROCHLORIDE to DYSPNOEA. This represents approximately 2.2% of all 110,881 adverse event reports for this drug.
Patients taking METFORMIN HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for METFORMIN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for METFORMIN HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 2,438 FDA reports for METFORMIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.2% of all adverse event reports for METFORMIN HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking METFORMIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.